High-dose	high-dose	O	O	O	O
tranexamic	tranexamic	CHEMICALS	O	OTHERS	I
Acid	acid	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
nonischemic	nonischemic	O	O	O	O
clinical	clinical	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
in	in	O	O	O	O
cardiac	cardiac	O	O	O	O
surgical	surgical	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
2	2	O	O	O	O
separate	separate	O	O	O	O
centers	centers	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
observed	observed	O	O	O	O
a	a	O	O	O	O
notable	notable	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
postoperative	postoperative	O	O	O	O
convulsive	convulsive	O	DISEASE	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
from	from	O	O	O	O
1.3	1.3	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
3.8	3.8	O	O	O	O
%	%	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
having	having	O	O	O	O
undergone	undergone	O	O	O	O
major	major	O	O	O	O
cardiac	cardiac	O	O	O	O
surgical	surgical	O	O	O	O
procedures	procedures	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
events	events	O	O	O	O
were	were	O	O	O	O
temporally	temporally	O	O	O	O
coincident	coincident	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
initial	initial	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
high-dose	high-dose	O	O	O	O
tranexamic	tranexamic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
TXA	txa	O	O	OTHERS	I
)	)	O	O	O	O
therapy	therapy	O	O	O	O
after	after	O	O	O	O
withdrawal	withdrawal	O	O	O	O
of	of	O	O	O	O
aprotinin	aprotinin	O	O	O	O
from	from	O	O	O	O
general	general	O	O	O	O
clinical	clinical	O	O	O	O
usage	usage	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
purpose	purpose	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
review	review	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
perform	perform	O	O	O	O
a	a	O	O	O	O
retrospective	retrospective	O	O	O	O
analysis	analysis	O	O	O	O
to	to	O	O	O	O
examine	examine	O	O	O	O
whether	whether	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
relation	relation	O	O	O	O
between	between	O	O	O	O
TXA	txa	O	O	OTHERS	I
usage	usage	O	O	O	O
and	and	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
after	after	O	O	O	O
cardiac	cardiac	O	O	O	O
surgery	surgery	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
An	an	O	O	O	O
in-depth	in-depth	O	O	O	O
chart	chart	O	O	O	O
review	review	O	O	O	O
was	was	O	O	O	O
undertaken	undertaken	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
24	24	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
perioperative	perioperative	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Electroencephalographic	electroencephalographic	O	O	O	O
activity	activity	O	O	O	O
was	was	O	O	O	O
recorded	recorded	O	O	O	O
in	in	O	O	O	O
11	11	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
formal	formal	O	O	O	O
neurological	neurological	O	O	O	O
evaluation	evaluation	O	O	O	O
and	and	O	O	O	O
brain	brain	O	O	O	O
imaging	imaging	O	O	O	O
studies	studies	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Twenty-one	twenty-one	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
24	24	O	O	O	O
patients	patients	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
have	have	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
new	new	O	O	O	O
cerebral	cerebral	O	O	OTHERS	I
ischemic	ischemic	O	O	OTHERS	I
injury	injury	O	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
were	were	O	O	O	O
likely	likely	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
ischemic	ischemic	O	O	OTHERS	I
brain	brain	O	O	OTHERS	I
injury	injury	O	O	OTHERS	I
in	in	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
did	did	O	O	O	O
not	not	O	O	O	O
have	have	O	O	O	O
permanent	permanent	O	O	O	O
neurological	neurological	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
.	.	O	O	O	O

All	all	O	O	O	O
24	24	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
received	received	O	O	O	O
high	high	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
TXA	txa	O	O	OTHERS	I
intraoperatively	intraoperatively	O	O	O	O
ranging	ranging	O	O	O	O
from	from	O	O	O	O
61	61	O	O	O	O
to	to	O	O	O	O
259	259	O	O	O	O
mg/kg	mg/kg	O	O	O	O
,	,	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
mean	mean	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
69.9	69.9	O	O	O	O
years	years	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
21	21	O	O	O	O
of	of	O	O	O	O
24	24	O	O	O	O
had	had	O	O	O	O
undergone	undergone	O	O	O	O
open	open	O	O	O	O
chamber	chamber	O	O	O	O
rather	rather	O	O	O	O
than	than	O	O	O	O
coronary	coronary	O	O	O	O
bypass	bypass	O	O	O	O
procedures	procedures	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
but	but	O	O	O	O
one	one	O	O	O	O
patient	patient	O	O	O	O
were	were	O	O	O	O
managed	managed	O	O	O	O
using	using	O	O	O	O
cardiopulmonary	cardiopulmonary	O	O	O	O
bypass	bypass	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
brain	brain	O	O	OTHERS	I
ischemic	ischemic	O	O	OTHERS	I
,	,	O	O	O	O
metabolic	metabolic	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
hyperthermia-induced	hyperthermia-induced	O	O	O	O
causes	causes	O	O	O	O
for	for	O	O	O	O
their	their	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
was	was	O	O	O	O
apparent	apparent	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Our	our	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
high-dose	high-dose	O	O	O	O
TXA	txa	O	O	OTHERS	I
in	in	O	O	O	O
older	older	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
conjunction	conjunction	O	O	O	O
with	with	O	O	O	O
cardiopulmonary	cardiopulmonary	O	O	O	O
bypass	bypass	O	O	O	O
and	and	O	O	O	O
open-chamber	open-chamber	O	O	O	O
cardiac	cardiac	O	O	O	O
surgery	surgery	O	O	O	O
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
clinical	clinical	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
in	in	O	O	O	O
susceptible	susceptible	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

